Amedisys 8K Regulation FD Disclosure | AMED 12 Nov 08

November 2008

www.amedisys.com

NASDAQ: AMED

Exhibit 99.1

Forward-Looking Statements

This presentation may include forward-looking statements as defined by the

Private Securities Litigation Reform Act of 1995. These forward-looking

statements are based upon current expectations and assumptions about our

business that are subject to a variety of risks and uncertainties. Additional

information regarding factors that could cause actual results to differ

materially from those discussed in any forward-looking statements are

described in reports and registration statements we file with the SEC,

including our Annual Report on Form 10-K and subsequent Quarterly Reports

on Form 10-Q and Current Reports on Form 8-K, copies of which are

available

the

Amedisys

internet

website

http://www.amedisys.com

or by

contacting

the

Amedisys

Investor

Relations

department

(800)

467-2662. We disclaim any obligation to update any forward-looking

statements in this presentation.

Investment Highlights

Focus on home nursing and related services

to Medicare population

Large, growing and highly fragmented industry

Strong internal growth and cash flow

with low recurring routine cap ex

Proven operating model supported

by sophisticated technology system

Demonstrated ability to identify

and integrate acquisitions

Liquidity availability to fund external growth

–

Unused revolver and additional balance sheet capacity

Extensive delivery platform ideally positioned

for Medicare care management initiatives

Experienced management team

William F. Borne

Chairman and Chief Executive Officer

CEO since founding the Company in 1982

Larry R. Graham

President and Chief Operating Officer

Joined Amedisys in 1996; COO since 1999;

President since 2004

Dale E. Redman, CPA

Chief Financial Officer

Joined Amedisys in February 2007

Alice Ann Schwartz

Chief Information Officer

Joined Amedisys in 1998, CIO since 2004,

SVP Clinical Operations since 2003

Jeffrey Jeter

Chief Compliance Officer

Joined Amedisys in 2001

Management Team

Corporate

Overview

Founded in 1982, publicly

listed 1994

511

locations in 35 states

Leading provider of home

health services

–

Services include skilled

nursing and therapy

94% of Home Health revenue

is episodic based (both

Medicare & non-Medicare)

For the nine-month period ended September 30, 2008

Both home health and hospice, inclusive of joint venture agencies, as of September 30, 2008

Forecasted 2008 annual results

14,500 employees

Daily visits = 18,400

6,750,000

annual visits

2008 revenue guidance = $1.175

billion

$1.3 billion market cap

Our

Locations

As of September 30, 2008, inclusive of joint ventures.

National home nursing provider located in 35 states.

Largest provider in the Southern and Southeastern United States.

–

465 home nursing

locations

–

46 hospice locations

Our Strategy

Focus on Medicare-eligible patients

Prioritize internal growth

Select, acquire and integrate quality home care agencies

Leverage cost-efficient operating platform

Develop and deploy specialized nursing programs

Expand care coordination platform

Source: CBO's

March 2008 Baseline: MEDICARE

MEDICARE Home Health and Hospice Revenue

$ in billions

Medicare Revenue Market Size

2006:

Medicare

spending

for home health reached

$14

billion

and

hospice

was $

9.2

billion,

giving

combined

total

$23.2

billion

2017:

Home

Health

will

contribute $

36 billion

and

hospice

$20

billion

the

projected $

56 billion

Home Nursing Market

Industry Growth Drivers

Trend from inpatient to home-based care:

–

Patient preference

–

Payor

incentives

–

Technology advancements

Demographics –

aging

population

–

8,000 Americans will become Medicare eligible each

day beginning in 2011 and by 2030, 57.8 million baby

boomers will be eligible for Medicare benefits

Increased prevalence of chronic and co-morbid conditions

According to the United States Census Bureau

Internal Growth

Internal revenue growth 28% for Q3 2008 and 27% for the

first nine months of 2008

Internal growth driven by:

Overall industry growth

Higher acuity levels and co-morbidities, requiring

more intensive services

Comprehensive range of clinical programs

Enhanced referral source education efforts

Focus

on start-ups

Start-Up Strategy

Start-ups

typically

generate

$1.5

$2.0

million in run-rate revenue by the end

of their second year of operations

~ 18 months to recoup the $250,000 -

$350,000 investment

20 home health start-ups completed

through September 30, 2008

* Reported numbers are for home health start-ups

Yearly Start-Ups

Acquisition Strategy

TLC Integration

TLC Integration Complete

Detailed plan to wind-down TLC corporate

Converted all agencies as

of September 15, 2008

Closed all regional billing centers as of

October 24 2008;

Minor number of corporate employees

remain until December 31, 2008

Investments in Technology

High Quality Health Care

Care Management

13 disease management programs

70 clinical tracks

Specialty Division

Balanced For Life first program in division

Targets higher acuity patients

Rolled out to 97 locations through

September 30, 2008; 160 total locations

targeted for roll out by year end 2008

Comprehensive Compliance Program

Local Level

•

Point-of-care system

enhances clinical

documentation accuracy with

real-time assessment input

•

Clinical nurse review of

assessments

•

Physician review/approval

•

Standardized care plans

•

Weekly case conferences

•

Monthly audits

•

End of episode case review

Regional Level

Corporate Level

•

Unannounced compliance

& billing audits

•

Regional directors monitor

compliance status and

resolve errors

•

Real-time monitoring

capability of local level

activity via Point of Care

system

•

Compliance training for all

employees

•

Compliance concerns hotline

•

Compliance review of metric

variances

•

Compliance manager site visits

•

Semi-annual clinical/compliance

reviews

•

Annual Sarbanes-Oxley audit

•

Annual billing competency

testing

http://www.amedisys.com/pdf/Compliance3/Compliance_Controls.pdf

Medicare Reimbursement

Implemented in October 2000

Base payment for 60-day episode of care

Adjusted for patient acuity and market factors

2008 CMS issued reimbursement changes

Expands HHRG from 80 to 153

More integrated reimbursement for therapy

Better alignment of reimbursement with patient needs

Allocation of more dollars to later episodes

Benefits agencies with a greater business mix of

higher-acuity patients

Financial Highlights

Increasing revenue

Cash flow/low cap ex requirements

Consistent EPS growth

Strong balance sheet to fund future growth

–

$250 million active shelf registration

–

$139

million unused revolving credit

facility through September 2008

$ earnings per diluted share

$3.25

After adding back certain expenses related to the integration

of TLC Health Care Services, Inc.)

EBITDA is defined as net income before provision for income taxes, net interest expense, and depreciation and amortization. EBITDA should not be considered as an alternative to,

or more meaningful than, income before income taxes, cash flow from operating activities, or other traditional indicators of operating performance. This calculation of EBITDA may

not be comparable to a similarly titled measure reported by other companies, since not all companies calculate this non-GAAP financial measure in the same manner.

($ millions, except per share data)

Summary Financial Results

2006

2007

3Q07

Net revenue

Period-over-period growth

Gross margin

Margin

Operating income

Margin

EBITDA

Margin

Fully-diluted EPS

Period-over-period growth

3Q08

Net Income

$541.1

41.8%

305.7

56.5%

65.7

12.1%

75.7

14.0%

38.3

$1.72

22.0%

$697.9

29.0%

368.9

52.9%

96.6

13.8%

114.0

16.3%

65.1

$2.48

44.2%

$180.9

32.0%

96.5

53.3%

25.7

14.2%

33.7

18.6%

20.2

$0.77

60.4%

$321.6

77.7%

170.4

53.0%

43.6

13.6%

49.4

15.3%

23.5

$0.87

13.0%

2006

2007

3Q07

Agencies at period end

Period-over-period growth

Episodic-Based Completed Episodes

Period-over-period growth

Episodic-Based Admissions

Period-over-period growth

Episodic-Based Revenue per Episode

Period-over-period growth

Total Visits

Period-over-period growth

3Q08

DSO

Inclusive of home health and hospice locations and joint ventures

360

30.9%

4,302,830

25.2%

129,649

19.9%

219,855

27.1%

$2,661

1.0%

51.3

275

3,437,881

108,140

172,930

$2,634

52.9

344

1,102,913

32,672

53,958

$2,672

49.3

511

48.5%

1,879,573

70.4%

53,203

62.8%

94,986

76.0%

$2,868

7.3%

56.7

Summary Performance Results

Summary Balance Sheet

($ in millions)

Dec. 31, 2007

Sept. 30, 2008

Assets

Cash

Accounts Receivable, Net

Property, Plant and Equipment

Goodwill

Other

Total Assets

Liabilities and Stockholders’

Equity

Debt

All Other Liabilities

Stockholders’

Equity

Total Liabilities and Stockholders’

Equity

$ 5.7

179.8

80.4

701.1

83.7

$ 1,050.7

$ 359.7

162.7

528.3

$ 1,050.7

$ 56.2

96.3

68.3

332.5

33.8

$ 587.1

$ 24.0

116.1

447.0

$ 587.1

Guidance

Provided as of the date of our form 8-K filed with the Securities and Exchange Commission on October 28, 2008

Calendar Year 2008

Net revenue:

$1.150 -

$1.175 billion

EPS:

$3.20 -

$3.25

(after adding back certain expenses related to

the integration of TLC Health Care Services, Inc.)

Diluted shares:

26.9

million

Summary

Focus on home nursing and related services

to Medicare population

Large, growing and highly fragmented industry

Strong internal growth and cash flow

with low recurring routine cap ex

Proven operating model supported

by sophisticated technology system

Demonstrated ability to identify

and integrate acquisitions

Liquidity availability to fund external growth

–

Unused revolver and additional balance sheet capacity

Extensive delivery platform ideally positioned

for Medicare care management initiatives

Experienced management team

Contact Information

Kevin B. LeBlanc

Director of Investor Relations

Amedisys, Inc.

5959 S. Sherwood Forest Boulevard

Baton Rouge, LA 70816

Office –

225.292.2031

Fax –

225.295.9653

kleblanc@amedisys.com

http://www.amedisys.com/compliance.cfm

Amedisys (AMED) 8-KRegulation FD Disclosure